(AMG 510) 20170543
27 Aug 2018
Trial Summary
A Phase 1, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation.
Acronym:
AMG 510
ACTRN/NCT /ethics:
NCT03600883
Scientific title:
A Phase 1, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation.
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18+ years |
| Sex | Both |
| Tumour Stream | Solid tumors |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2018-08-27 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6410 |
| Principal Investigator | Professor Tim Price |
| Recruitment Status | Completed |